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Abstract 
Drug development consists of many sequential and parallel steps; failure in one of the steps can lead to 
discontinuation of the process. The process is time-consuming and very expensive, especially the clinical 
phase. In order to enhance cancer drug development in the 1980s, the National Cancer Institute (NCI) 
adopted a new screening system using 60 different tumour cell lines from various histologies.  All standard 
drugs were tested in this panel and it is still open for testing of new chemical entities (NCE) of potential 
interest. The European NCI compounds initiative, a collaborative programme of the NCI, the Cancer 
Research Campaign (CRC; now CRUK) and the Pharmacology and Molecular Mechanism Group (PAMM) of 
the EORTC (European Organization on Research and Treatment of Cancer), was initiated in 1993. The 
programme aimed to help the NCI reducing its backlog of in vivo testing by further evaluation of interesting 
European compounds using a pharmacologically directed approach. Considerable multidisciplinary 
expertise in drug development was combined by the CRC and EORTC-PAMM: chemists, pharmacists, 
biologists, pharmacologists, oncologists. Selection criteria for European NCI compounds included novelty of 
the NCE, in vitro activity, if available in vivo and hollow fibre activity, and COMPARE negativity. Over a 
period of more than 20 years 95 out of approximately 2,000 reviewed compounds were selected. These 
compounds were put through a series of stepwise pharmacological tests comprising solubility (suitable 
formulation to administer the NCE to mice), feasibility to develop a simple analytical assay (usually HPLC), 
limited toxicology and angiogenic properties. This paper provides examples to illustrate the rigorousness of 
the elimination process of the compounds and discusses the way to improve the process by inclusion of 
more physico-chemical parameters. 
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Anticancer drug development is a collaborative effort. When a compound has been synthesised 
chemically or isolated from a specific source, e.g. a natural product, it will be characterised chemically, 
physically, pharmacologically, pharmaceutically, toxicologically and biologically, requiring the input from 
various disciplines. When a compound passes all these steps successfully it continues to clinical 
development [1]. A tightly controlled process precedes the first administration to a patient. This process is 
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subject to many regulations and requires approval by local hospital medical ethical review boards and 
national competent authorities. This first step is the Phase I clinical study, in which the safety, side effects 
and best dose of a drug are determined. The latter can be the maximum tolerated dose (MTD) for 
cytotoxics or the maximum effective dose (usually lower than the MTD) for compounds affecting signaling 
pathways. This dose is used to determine the antitumor activity of the agent in a Phase II study [1-3]. In the 
classical drug development setting, an active compound (antitumor activity comparable to that of standard 
therapy), will proceed to a randomised Phase III study in which the new drug will be compared to the 
standard therapy or placebo. However, with several novel compounds in which a target is defined, a Phase I 
study may be expanded to include only patients with predefined biomarkers [3]. Drugs can obtain market 
approval from Medicines agencies such as the EMA and FDA, based on an extensive risk/benefit ratio 
evaluation. 
An increasing understanding of cancer biology leads to a heterogeneity at multiple levels (genetic, 
functional, tumour components, signalling pathways), which translates into an increasing number of 
products in the pipeline of pharmaceutical companies. This high number of compounds resulted in more 
Phase I, II and III clinical trials requiring even more patients, which led to extensively high costs for 
pharmaceutical industry and subsequently health care in society [4,5]. These numbers (costs and number of 
patients) are increasing in the last decades [6], while the rate of success in oncology drug development is 
limited, compared to other diseases [7]. In order to keep the costs as low as possible it is important that 
every aspect of the development process is critically reviewed, including optimisation of drug selection at 
an early stage. 
The European Organization for Research and Treatment of Cancer (EORTC) is the largest European 
organization coordinating clinical studies in the development of new cancer therapies [8]. The National 
Cancer Institute (NCI) in Bethesda, MD, USA, developed in the 2nd half of the 1980s a 60-cell line panel 
(called NCI-60 panel throughout this paper), consisting of 60 cell lines representative for the 9 major 
tumour types, with the aim to select compounds that show selective potency against one of these 
malignancies [9]. This NCI-60 panel was offered to the scientific community to test the potency of Novel 
Chemical Entities (NCEs) and since that period hundreds of thousands of compounds have been submitted 
to the NCI screen, but not all passed the initial NCI selection procedure and were not tested. Several tested 
compounds showed an interesting profile and were candidates for further development e.g. in vivo testing, 
but early in this process it was recognized that too many compounds fulfilled the criteria for in vivo testing. 
In order to speed up the backlog in this development and since many compounds came from Europe, an 
international academic collaboration between both sides of the Atlantic was initiated in 1993, between the 
EORTC Research Branch, the Cancer Research Campaign (CRC, now CRUK) and the NCI, the so-called 
European NCI compounds initiative, which focused on compounds synthesised in Europe and showing 
interesting data in the NCI screen. CRC and EORTC set up a review committee to select European 
compounds for further development [10,11]. About 2,000 compounds were evaluated by the CRC-EORTC 
review committee in >20 years and 95 were selected for further evaluation. Further details on this process 
and the achievements have recently been summarised [10]. The purpose of this paper is to evaluate 
mechanistic details e.g. ADME (Absorption, Distribution, Metabolism, Excretion) in this process by 
describing the development of several compounds that either failed or were successful. Successful means 
moving into Phase I or eventually Phase II clinical studies. Failure may have been caused by obvious 
parameters, such as lack of potency, poor solubility, stability and other physico-chemical properties. 
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The process of European NCI compound evaluation  
In the early 1990s, the screening’s capacity of the NCI-60 panel was 10,000 compounds annually. NCEs, 
submitted by scientists from all over the world, are selected for screening based on structural diversity and 
novelty of the compound. In the initial program selected NCEs were tested at 5 different concentrations 
(varying over 5 logs: 10-4–10-8 or 10-5–10-9 M) and cells were exposed for 48 hours to the drug. Three 
parameters were determined for each drug: the GI50 (or IC50: 50 % growth inhibition), the TGI (total 
growth inhibition) and the LC50 (50 % cell kill or 50 % lethal concentration) (Figure 1) [12].  The results of 
the screen are reported as growth inhibition curves as shown in Figure 2 for compound NSC-625492. Many 
current drug sensitivity tests often denote these curves as viability curves. This is not a correct terminology, 
because growth inhibition is measured. The NCI data are summarized as mean graphs for GI50, TGI or LC50 
values. These mean graphs depict whether a cell line is more or less sensitive than the GI50/TGI/LC50 mean 
of the test drug in the NCI-60 panel. Figure 3 shows the mean graphs of compound NSC-710305 [13], also 
known as Phortress, and a prodrug of Phortress 5F-203. These mean graphs demonstrate a tumour specific 
sensitivity for lung, ovarian, renal and breast cancer (bars to the right). Subsequent mechanistic studies 
were performed according to the guidelines published recently [14]. 
 
Figure 1. Example growth inhibition curves after 48 hours exposure to a hypothetical drug tested at 0.1 to 
1000 nM in three lung cancer cell lines. Three parameters are shown: the GI50 (the concentration that gives 
50 % growth inhibition, often also referred to as IC50), the TGI (the concentration that gives a total growth 
inhibition meaning that the number of cells at the end of the exposure is similar to that at the beginning) and 
the LC50 (the concentration that gives 50 % cell kill, meaning that at the end the number of cells is 50 % of 
the number of cells at the beginning). Values are calculated according to the NCI protocol: 
https://dtp.cancer.gov/discovery_development/nci-60/methodology.htm 
When positive, such as for Phortress, compounds were further screened in a human tumour xenograft 
(HTX) panel. However, the NCI screen yielded too many potential compounds for HTX testing, so that a fast 
low-cost preliminary in vivo screen was developed, the so-called hollow fibre assay (HFA) [15,16]. This assay 
combines advantages of in vitro screens (relatively fast, several tumour types together) and bypasses the 
disadvantages such as the poor predictive capacity for in vivo activity and lack of information on potential 
pharmacological properties. The latter are important to determine the amount of drug to be delivered [17]. 
The HFA appeared to predict for HTX activity [18,19]. 
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Figure 2. Example of a typical NCI-60 cell line growth inhibition report for compound NSC-625492.  Each panel 
represents cell lines derived from of a particular type of cancer (left to right, top to bottom): 5 breast cancer 
cell lines), 8 central nervous system (CNS) cell lines, 9 colon cancer cell lines, 6 leukaemia cell lines, 11 
melanoma cell lines, 11 non-small cell lung cancer (NSCLC) cell lines, 7 ovarian cancer cell lines (including one 
with P-glycoprotein overexpression), 2 prostate cancer cell lines, 9 renal cancer cell lines).  The two small cell 





and cells were exposed for 48 hr. Obtained from the NCI DTP database 
https://dtp.cancer.gov/discovery_development/nci-60/methodology.htm.   
In addition to the potency of the drugs (e.g. Figure 2), the selectivity for a certain tumour type in vitro 
(mean graph, Figure 3), the HFA and if available the HTX data, another important selection criterion for the 
European NCI compounds were the COMPARE data [20]. COMPARE is a comparison tool developed by the 
NCI based on the sensitivity profile of an NCE compared to the whole database. COMPARE-positive 
compounds (Pearson correlation coefficient ≥0.8) often showed the same mechanism of action; these 
compounds could be structurally related but also unrelated compounds [9,12]. Since COMPARE-negative 
compounds (Pearson correlation coefficient <0.8) usually did not have close matches in the COMPARE 
programme, they might have a novel mechanism of action and were thought to be most interesting. 
For administration of drugs to animals often additional hurdles needed to be solved, such as the 
administration vehicle, which will be different from formulations used in vitro [14]. Many compounds were 
poorly soluble and specific formulations were used, dependent on the compound, but keeping in mind 
what might be suitable for future administration to patients. Hence dimethyl sulfoxide (DMSO) might be 
suitable for in vitro and in vivo to mice, but not for patients (Table 1). After this pre-formulation step, the 
potential bioavailability of a compound was investigated. After the development of a suitable HPLC assay 
(or another analytical assay) and using a proper formulation, the MTD in mice was determined. The MTD 
was administered and plasma pharmacokinetics determined at various time points to ascertain whether 
the drug would reach plasma concentrations in the range of the in vitro GI50. Subsequently, this dose and 
schedule were used to explore whether the compound would have suitable in vivo antitumor activity. If so, 
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the development was continued and if not, stopped. In the next section, several examples of such a 
development will be presented. 
 
Figure 3. Example report of drug selectivity for 5F-203 and its prodrug Phortress (source NCI DTP). Values are 
calculated relative to the mean GI50 for each compound. Differences compared to the mean are given as a 
log 10 value, with bars to left representing less sensitive cell lines (10
3
 to 0) and those to the right more 
sensitive cell lines (0 to 10
-3
).  Cell lines from top to bottom represent 5 leukaemia cell lines, 9 NSCLC, 7 colon 
cancer, 6 CNS, 8 melanoma, 6 ovarian cancer, 8 renal cancer, 2 prostate cancer, 8 breast cancer (including 
one with P-glycoprotein overexpression). Please note that the composition of this panel is different from 
Figure. 2. The most sensitive cell lines are depicted in a larger font. The non-responsive in Italics. 
Examples of selected compounds 
In one of the early selected series of compounds, NSC-697786 (Figure 4) showed an interesting profile in 
the COMPARE analysis with a COMPARE coefficient of 0.503 for methotrexate, 0.498 for DUP785 
(Brequinar), 0.496 for N-phosphon-acetyl-L-aspartate (PALA) and 0.474 for trimetrexate. This indicates 
some similarity with antifolates (methotrexate and trimetrexate) and pyrimidine de novo nucleotide 
inhibitors (DUP785 and PALA). The standard approach to exclude this is a comparison in cell lines with 
aberrations in folate metabolism and to perform rescue experiments with normal pyrimidine nucleosides, 
respectively. Consequently, this compound was tested in  colon cancer WiDr cells grown in standard culture 
medium (which has a high folate concentration) and WiDr cells that are adapted to a low physiological 
(comparable to human plasma; WiDr/F) folate concentration [21]. A similar IC50 was found in both lines 
(0.26 ± 0.06 and 0.25 ± 0.07 µM, respectively; means ± SE of 4-7 experiments; 72-hour exposure). WiDr/F 
cells are more sensitive to antifolates such as methotrexate. Addition of 1 or 5 mM uridine or cytidine did 
not protect the cells, which would have been indicative for a pyrimidine de novo inhibition [22]. FMA3 wild 
type and FMA3/TK- (thymidine kinase deficient) [23] were similarly sensitive (IC50 values for NSC-697786 
3.2 ± 0.2 and 2.0 ± 0.8 µM), which excluded a role for thymidine kinase. It was concluded that this 
compound is a not acting as an antimetabolite, and had possibly unique mechanism of action. However, it 
was discontinued due to lack of in vivo activity, possibly because of poor pharmacokinetics. 
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water    10% (final) 
0.9% Saline pH 7.4  0.5 ml Mice; rats 2
nd
 choice 
Saline pH 2.0 








Ethanol 10% 10 ml/kg Mice (i.v.) 1% 
Dimethylsulfoxide 
(DMSO) 
10% in water 
1% in water 




Mice  (i.v.; p.o.) 
Mice (i.p.) 
Rats (dx5) 
0.25%  (0.1% 
preferable) 
Dimethylformamide     
0.125 % (upper 
limit) 
Tween 80 
10% in water 











Mice (i.v., slow) 
Mice (i.p) 
 
 50%/25% 0.2 ml Rats (dx5)  
N-methyl glucamine 1% in water 10 ml/kg Mice (p.o.)  
Carboxymethyl 
cellulose 
1% in water 10 ml/kg Mice (i.p)  
Cremophor EL 5% in water 10 ml/kg Mice (i.v.)  
NaHCO3 5% in water 10 ml/kg Mice (i.v.)  
N,N-Dimethyl-
acetamide (DMA)  
10% in  water 10 ml/kg Mice (i.p.)  
DMA  10% in arachis oil 10 ml/kg Mice (i.p.)  
Guidelines developed by the Joint Formulation Working party of the Screening and Pharmacology Group (SPG) which was 
continued as a PAMM sub-committee and renamed into: Drug Discovery Committee (DDC) [11] 
A completely different compound, NSC-625492 was selected for its unique molecular structure being a 
bismuth analogue (Figure 4). The GI50 was low (0.3 µM) with activity in many tumour types (colon, ovarian, 
non-small cell lung cancer and leukaemia; Figure 2). It was thought that it might form DNA adducts, 
because of its similarity to other heavy metals (e.g. platinum). Using this property, an assay using flameless 
atom absorption spectroscopy (FAAS) as used for cisplatin [24], was set up to determine its in vivo 
pharmacokinetics. The compound indeed showed interaction with DNA, but was not cross-resistant against 
cisplatin resistant cell lines and was active in P-glycoprotein expressing cell lines. Using a formulation of 
10 % DMA and arachis oil, the MTD was 30 mg/kg (8 % weight loss), which was used to determine its 
plasma pharmacokinetics (Figure 5) and potential antitumor activity. NSC-625492 did not show a typical 
bell-shaped plasma profile curve, but the concentrations remained relatively constant over a 24-hr period, 
possibly indicating a lack of metabolism. Although sufficiently high plasma concentration (> GI50) were 
found, a long retention and no protein binding (in contrast to cisplatin), there was no in vivo activity against 
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various tumour models. The development of the compound was therefore discontinued. 
NSC-637828 also showed an interesting COMPARE negative profile (correlation coefficients < 0.625) 
with rifamycin and the nitrogen mustard CCNU (Lomustine;  1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea) 
being the highest. It was insoluble and a suspension could only be obtained in 10 % DMA + arachis oil (but 
not in DMSO or ethanol), which showed acceptable toxicity (< 10 %). Due to these properties an adequate 
HPLC method could not be established and drug sensitivity studies could not be completed. Therefore, the 
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Figure 4. Structural formulas and some physico-chemical properties of several of the investigated 
compounds. 
Two examples of drugs with completely different mechanisms of action are the combretastatin A-4 
analogues and NSC 734237, a Paullone-like molecule. These two drugs were investigated in a collaborative 
effort of various PAMM laboratories and the NCI Drug Development and Target Analysis Branches. 
Combretastatin A-4 is a poorly soluble natural product and its more soluble metabolite combretastatin A-4 
phosphate disrupts endothelial junctions of tumour blood vessels by preventing microtubule 
polymerisation in endothelial cells of tumour blood vessels; this resulted in tumour necrosis [25,26]. 
Various analogues (NSC736359, NSC736992, and NSC733436) with a high potency (nM-µM range) were 
further analysed, but moderate antitumor activity was observed [27], possibly because under these 
conditions the density (size and number) of CD31+ blood vessels was not affected.  
The Paullone-like molecule NSC 734237 is an isoindoloquinoxaline with low to sub µM IC50 values [28] 
for CNS, colon, melanoma and breast cancer lines. However, the compound was quite insoluble (6 % active 
drug in a liposomal formulation), but showed antitumor activity against a doxorubicin-resistant, oestrogen 
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receptor negative human breast cancer xenograft MT-3/ADR with a reduction in both CD31+ microvessel 
density and Ki-67. Hence the drug showed antivascular effects and cytotoxic activity, which are most likely 
due to inhibition of tubulin polymerisation and topoisomerase I, respectively. More water soluble 
analogues were investigated further, but did not improve the overall result. In the future, such compounds 
should optimally be investigated more extensively for their oral bioavailability and their formulation 
adapted. 
 
Figure 5. Concentration time curves of NSC-625492. Mice were injected with 30 mg/kg NSC-625492 in 10% 
DMA in arachis oil. For the pharmacokinetics study mice were sacrificed at 0.25, 3, 6 and 24 h and blood was 
collected by heparinization to prepare plasma. Total bismuth was measured by mixing 1 volume of plasma 
with 5 volumes of triton/antifoam (1/1) and 4 volumes of 0.4 M HCl, which was directly introduced into the 
AAS (Varian SpectrAA 300 Zeeman with certified Bi-lamp; λ=306.8 nm). Calibration lines were obtained with 
bismuth nitrate from 0.17 to 3 μM. Free bismuth (non-protein bound) was measured in the supernatant after 
deproteinization (1 volume of plasma mixed with 2 volumes of ethanol and put at -20 °C for 2 hr followed by 
centrifugation for 10 min at 4000 g) 
However, several compounds that showed an interesting profile in the NCI-screen, were also successful 
at further evaluation, such as DRH-147 and Phortress. DRH-417, a pyrrolobenzodiazepine monomer acts by 
binding into the minor groove of DNA and was very potent in the NCI 60-panel (mean IC50 3 nM) and at 
subsequent testing by investigators of the European NCI compounds group [29]. It showed favourable 
pharmacokinetics (plasma peak levels of 171 nM, far above the GI50 value) and interesting in vivo activity 
against several HTX models (p<0.01). These data led to the development of SJG-136, a 
pyrrolobenzodiazepine dimer that went into a clinical Phase I study and Phase II studies in ovarian cancer 
and leukaemia [30]. 
Phortress (Figure 3) is a water-soluble benzothiazole prodrug of 5F-203, that is active (low nanomolar 
GI50), and selective against breast, ovarian and lung cancer [31]. 5F-203 binds to cytoplasmic aryl 
hydrocarbon receptors, forming a complex that is translocated to the cellular nucleus, and subsequently 
binds to the cyp1a1 promoter [32,33]. This leads to an induction of the expression of cytochrome P450 1A1, 
responsible for metabolism of 5F-203 to a bio-reactive species that forms DNA-adducts. This unique 
mechanism of action, together with a good pharmacokinetic profile, led to further evaluation in Phase I 
clinical study [34], in which 14 out of 42 patients had stable disease. All together, these data show that the 
approach can lead to compounds with clinical activity. 
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Figure 6. Flow chart showing the testing procedure and addition of novel parameters as outlined in the text. 
Each step can lead to elimination when not full-filling the criteria. NCE, new chemical entity;  MTD, maximal 
tolerated dose; HFA, hollow fiber assay. 
The first three examples show that despite initial enthusiasm about the drug sensitivity profile and 
COMPARE data, development had to be discontinued rapidly. Unfavourable physico-chemical properties, 
such as insolubility, made it impossible to perform adequate in vitro and in vivo studies and to set up 
suitable analytical assays. In addition to this and lack of in vivo activity, other reasons for discontinuation 
included instability, impurity, unavailability of material and insufficient bioavailability. A careful analysis of 
the mechanism of action helps to understand the success (DRH-147 and Phortress) but also enabled a 
systematic development of novel analogues. This was due to a successful scientific collaboration between 
different groups that provides a model for future drug development. Importantly the groups adhered to 
standard cellular pharmacology tools for testing [14]. 
Conclusions 
The results of the pharmacologically directed approach clearly showed that a few simple procedures 
with small numbers of mice quickly allow discontinuing agents that were highly unlikely to have any 
antitumor activity. The process is outlined in the flow chart (Figure 6). The chart also shows some 
streamlining to optimize the process and eliminate agents with unsuitable pharmacological parameters in 
less than three months. Current approaches should put much more emphasis on physico-chemical 
properties such as solubility, pKa values, log P and log D values, protein binding and drug distribution. This 
serves two purposes, whether to discontinue development rapidly or when promising how to design an 
analogue with better properties. Regarding solubility, there are novel possibilities to use insoluble 
compounds with adequate solvents [35]. Using biomimetic approaches one would be able to gain insight in 
elimination constants, and likelihood of brain uptake [36]. Next to that, pharmacological evaluation should 
include Phase I (oxidation) and II (conjugation) drug metabolism which can currently easily being studied 
using isolated hepatocytes. Inclusion of such novel approaches would more rapidly predict whether a drug 
will have suitable pharmacological properties to proceed to the next step in development. 
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